Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Q/C Technologies, Inc.

Capitalization 16.63M 14.48M 13.11M 12.51M 22.75M 1.53B 23.59M 156M 61.91M 734M 62.39M 61.07M 2.65B P/E ratio 2023
-1.46x
P/E ratio 2024 -0.1x
Enterprise value 8.12M 7.07M 6.4M 6.11M 11.11M 749M 11.52M 76.07M 30.23M 359M 30.46M 29.82M 1.29B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
94.88%
Yield 2023 *
-
Yield 2024 -
1 day+3.12%
1 week-2.46%
Current month+6.43%
1 month+2.32%
3 months-21.07%
6 months+0.51%
Current year-0.50%
1 week 3.66
Extreme 3.66
4.25
1 month 3.38
Extreme 3.38
4.97
Current year 3.38
Extreme 3.38
6.33
1 year 2.5
Extreme 2.5
44.4
3 years 2.5
Extreme 2.5
7,050.01
5 years 2.5
Extreme 2.5
29,850.03
10 years 2.5
Extreme 2.5
29,850.03
Manager TitleAgeSince
Director of Finance/CFO 52 31/01/2021
President 74 13/06/2024
Director TitleAgeSince
Chairman 56 31/08/2025
Director/Board Member 65 07/08/2017
Director/Board Member 74 07/04/2024
Change 5d. change 1-year change 3-years change Capi.($)
+3.12%-2.46%-89.21%-99.93% 16.54M
+3.98%+1.77%+11.03%+199.97% 53.69B
+8.08%+15.71%+523.30%+1,408.05% 14.93B
+13.88%+13.00%+124.90%+8.29% 10.64B
+8.19%+9.87% - - 5.95B
+2.91%+11.94%+92.62% - 5.35B
-11.76%-1.98%-14.32%+1,019.35% 2.92B
+6.60%+7.39%-29.76% - 2.52B
+2.31%-1.84% - - 1.83B
Average +1.64%+8.26%+88.37%+507.15% 10.87B
Weighted average by Cap. +1.28%+6.76%+112.27%+423.68%

Financials

2023 2024
Net sales - -
Net income -4M -3.48M -3.15M -3.01M -5.47M -369M -5.68M -37.48M -14.9M -177M -15.01M -14.69M -637M -23.36M -20.35M -18.42M -17.58M -31.97M -2.16B -33.15M -219M -86.99M -1.03B -87.66M -85.81M -3.72B
Net Debt -4.87M -4.25M -3.84M -3.67M -6.67M -450M -6.92M -45.68M -18.15M -215M -18.29M -17.91M -777M -8.51M -7.41M -6.71M -6.4M -11.64M -785M -12.07M -79.73M -31.68M -376M -31.93M -31.25M -1.36B
Logo Q/C Technologies, Inc.
TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on developing novel therapies for age-related diseases and autoimmune and inflammatory conditions. It is focused on developing and commercializing two therapeutic platforms based on well-defined therapeutic targets: MYMD-1 and Supera-CBD. MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. Supera-CBD is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the growing CBD market, which includes both Food and Drug Administration (FDA) approved drugs and CBD products not currently regulated as drugs.
Employees
2
Date Price Change Volume
16/03/26 3.970 $ +3.12% 619,985
13/03/26 3.850 $ +2.12% 187,378
12/03/26 3.770 $ -1.82% 239,918
11/03/26 3.840 $ -4.48% 361,715
10/03/26 4.020 $ -1.23% 352,990
SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW